• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 172

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

Logan Davidson – American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse...

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Numinus Wellness Inc. Reports Q2 2022 Results

PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying...

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

MYND Life Sciences Announces $3.5 Million Share Offering

1...171172173...303Page 172 of 303

EDITOR PICKS

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the...

Logan Davidson – American Ibogaine, State Strategy, and the Future of...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©